LANCE STEIN: Open Payments
NPI 1568558062 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$314,704 in 271 payments from 22 companies in 2025. Trend: 2023 $73,693 · 2024 $191,860 · 2025 $314,704
Speaker / faculty: $281,600Consulting: $17,324Travel & lodging: $8,934Food & beverage: $6,846
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 87 | $136,878 |
| Ipsen Biopharmaceuticals, Inc | 45 | $75,188 |
| Mallinckrodt Hospital Products Inc. | 32 | $60,493 |
| Gilead Sciences, Inc. | 38 | $22,205 |
| ABBVIE INC. | 13 | $14,685 |
| Bausch Health US, LLC | 1 | $2,188 |
| Intercept Pharmaceuticals, Inc. | 13 | $1,467 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $729 |
| Novo Nordisk Inc | 6 | $254 |
| Fujifilm Healthcare Americas Corporation | 1 | $125 |
Products named: REZDIFFRA, TERLIVAZ, IQIRVO, Livdelzi, Bylvay, MAVYRET, OCALIVA, XIFAXAN.
Industry payments across GA — which companies pay providers there.
